TPST Profile
Tempest Therapeutics Inc. is a dynamic clinical-stage oncology company focused on developing innovative small molecule therapeutics for the treatment of various cancers. The company’s research and development efforts are directed towards targeting key pathways involved in tumor growth and immune evasion. Tempest Therapeutics is advancing two prominent clinical programs: TPST-1495 and TPST-1120. TPST-1495 is a dual antagonist targeting the EP2 and EP4 receptors of prostaglandin E2, a signaling molecule implicated in promoting tumor growth and immune suppression. This drug is currently undergoing Phase 1 trials to evaluate its efficacy and safety in treating solid tumors.
The second major clinical candidate, TPST-1120, is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). This receptor plays a critical role in regulating lipid metabolism and has been associated with cancer progression. By targeting PPARα, TPST-1120 aims to disrupt the metabolic pathways that support tumor growth. This therapeutic is also in Phase 1 trials for solid tumors, with the goal of demonstrating its potential to improve patient outcomes through targeted action.
In addition to its clinical programs, Tempest Therapeutics is developing TREX-1, an enzyme crucial for regulating the innate immune response within tumors. TREX-1 modulates the immune environment and can influence how effectively the body’s immune system responds to cancer. By targeting TREX-1, Tempest Therapeutics aims to enhance the ability of the immune system to recognize and attack tumor cells, potentially leading to more effective and durable cancer treatments.
Founded in 2011 and headquartered in South San Francisco, California, Tempest Therapeutics was formerly a subsidiary of Inception Sciences, Inc. The company’s commitment to advancing cancer therapeutics is underscored by its innovative approach to targeting critical pathways in tumor biology and immune response. Tempest Therapeutics continues to focus on bringing forward new treatment options that address unmet needs in oncology and improve the lives of cancer patients.
|
